case_images: PMC5844437_01
case_images: The tumor is composed of cells with hyperchromatic nuclei, no nucleoli, scant cytoplasm, and nuclear molding, with numerous mitoses (hematoxylin-eosin, 400x).
case_images: 10.1177_2324709618760644-fig1.jpg
case_images: PMC5844437_01_10.1177_2324709618760644-fig1.jpg
case_images: fig1-2324709618760644
case_images: High-power evaluation (400x) demonstrated tumor cells with hyperchromatic nuclei, no nucleoli, scant cytoplasm, and nuclear molding, with numerous mitoses (Figure 1).
case_images: The tumor has neuroendocrine features as shown by positivity with antibodies to CD56 (400x).
case_images: 10.1177_2324709618760644-fig2.jpg
case_images: PMC5844437_01_10.1177_2324709618760644-fig2.jpg
case_images: fig2-2324709618760644
case_images: The tumor has neuroendocrine features as shown by positivity with antibodies to CD5 (Figure 2) and synaptophysin (Figure 3).
case_images: The tumor has neuroendocrine features as shown by positivity with antibodies to synaptophysin (400x).
case_images: 10.1177_2324709618760644-fig3.jpg
case_images: PMC5844437_01_10.1177_2324709618760644-fig3.jpg
case_images: fig3-2324709618760644
case_images: The tumor has neuroendocrine features as shown by positivity with antibodies to CD5 (Figure 2) and synaptophysin (Figure 3).
case_images: p53 mutation is shown by positive nuclear staining with antibody to p53 (400x).
case_images: 10.1177_2324709618760644-fig4.jpg
case_images: PMC5844437_01_10.1177_2324709618760644-fig4.jpg
case_images: fig4-2324709618760644
case_images: The tumor is a carcinoma as evidenced by positivity with antibodies to CK7 (400x).
case_images: 10.1177_2324709618760644-fig5.jpg
case_images: PMC5844437_01_10.1177_2324709618760644-fig5.jpg
case_images: fig5-2324709618760644
case_images: The tumor is a carcinoma as evidenced by positivity with antibodies to cytokeratin AE1/AE3 (400x).
case_images: 10.1177_2324709618760644-fig6.jpg
case_images: PMC5844437_01_10.1177_2324709618760644-fig6.jpg
case_images: fig6-2324709618760644